Islands Dispute Hits Japan Device Sales In China While Pharma Less Affected
This article was originally published in PharmAsia News
Executive Summary
Both Japanese and Chinese device makers have reported lower sales and profits linked to a rift over disputed islands, potentially signaling a lengthy period of strained trade ties.
You may also be interested in...
Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines
TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule
Japanese Regulators, With Drug Makers Support, Moves Toward East Asian Clinical Data Sharing And Acceptance
Japan is determined to further an initiative in promoting multi-regional clinical study data acceptance among East Asian countries, and the proposal has gained critical support from the nation's drug making industry
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.